This combination contains Ramipril 5 mg and Metoprolol Succinate 47.5 mg (equivalent to Metoprolol Tartrate 50 mg). It is an advanced cardiovascular formulation designed for effective management of hypertension and heart-related conditions. Ramipril is an ACE inhibitor that relaxes blood vessels by blocking the formation of angiotensin II, thereby reducing blood pressure and improving cardiac efficiency. Metoprolol Succinate is a cardioselective beta-blocker that reduces heart rate, myocardial oxygen demand, and blood pressure by blocking beta-1 receptors in the heart. Together, this dual-action therapy provides superior blood pressure control, reduces cardiovascular risk, prevents heart failure progression, and lowers the risk of heart attacks and strokes. The sustained-release form of Metoprolol ensures 24-hour blood pressure control and improved patient compliance. This combination is widely prescribed for: Essential hypertension Chronic heart failure Post-myocardial infarction management Coronary artery disease Cardiovascular risk reduction
